Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present PixarBio Corporation (OTC: PXRB).

Full DD Report for PXRB

You must become a subscriber to view this report.



Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-14N/A0.01N/AN/A0
2018-12-130.010.010.010.011,000
2018-12-120.020.020.020.02220
2018-12-11N/A0.06N/AN/A0
2018-12-10N/A0.06N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2017-01-201,9406,22531.1647Cover
2017-01-193,1459,47833.1821Cover
2017-01-1819,94695,61920.8599Cover
2017-01-174,70015,92029.5226Cover
2017-01-121,0001,000100.0000Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PXRB.


About PixarBio Corporation (OTC: PXRB)

Logo for PixarBio Corporation (OTC: PXRB)

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre clinical and commercial development of novel neurological drug delivery systems for post operative pain. PixarBio researches and develops targeted delivery systems for drugs, cells, or biologics to treat pain, epilepsy, Parkinson s disease, and spinal cord injury. Our lead product platform, NeuroRelease, is an extended drug release microparticle platform that is non opiate, non addictive for post surgical pain treatment. In pre clinical models NeuroRelease has the potential to achieve months of sustained therapeutic release of non opiate drugs for post operative, acute and chronic pain.

 

 

 

Current Management

  • Frank M. Reynolds / CEO, CFO, Principal Acct. Officer
    • Francis M. Reynolds has served as the CEO, CFO, CSO and Chairman of the Board of Directors of PixarBio since August . Mr. Reynolds cofounded PixarBio in . From to August , Mr. Reynolds served as the Chairman of the Board, CEO, CSO, and CFO of InVivo Therapeutics Corp, a research and clinicalstage biomaterials and biotechnology company he founded in . Due to a fractured foot which took months to heal, Mr. Reynolds retired from InVivo Therapeutics in August . He is a coinventor on over neurological biomaterials focused patent applications. As the former Director of Global Business Development at Siemens, Mr. Reynolds was responsible for new business in over countries. He obtained an MBA from MITSloan Fellows Program in Global Innovation and Leadership at Massachusetts Institute of Technology in a Master s of Science in Technology Management from The Wharton School in a Master s of Science in Engineering from University of Pennsylvania in a Master s of Science in Management Information Systems from Temple University in a Master s of Science in Health Administration from Saint Joseph s University in a Master s of Science in Counseling Psychology from Chestnut Hill College in and a Bachelor of Science in Marketing from Rider University in .
  • Katrin Holzhaus / Chief Admin. Officer
    • Katrin Holzhaus cofounded PixarBio as Chief Operating Officer and has served as Chief Administration Officer and a Director of PixarBio since September . Having worked in the executive suite with PixarBio cofounder and CEO Frank Reynolds for almost years she has had a front row view to revolutionary neurological R amp D models that have led to breakthrough treatments for spinal cord injury and pain. Initially with Expand the Knowledge, InVivo Therapeutics Holdings Corp NVIV , and now with PixarBio, Ms. Holzhaus brings complimentary leadership skillsets to PixarBio s operations team and a proven record of success. At PixarBio, Ms. Holzhaus oversees the Company s administrative and resource allocation including longrange financial planning and budgeting, business and contractual services, research support, human resources, facilities planning. From July to August , Ms. Holzhaus served as Senior Executive Assistant at InVivo Therapeutics a pharmaceutical company. From June to July , she was Director of Operations at Magnum Group, Inc., a global communications company supporting clients in the life sciences sector. Ms. Holzhaus received her MBA and MS in Management Information Systems from Temple University, Philadelphia, Pennsylvania in and a Master of Arts from Leipzig University, Germany in .
  • Kenneth Stromsland / VP, Investor Rel., CIO
  • Frank M. Reynolds / Chairman
    • Francis M. Reynolds has served as the CEO, CFO, CSO and Chairman of the Board of Directors of PixarBio since August . Mr. Reynolds cofounded PixarBio in . From to August , Mr. Reynolds served as the Chairman of the Board, CEO, CSO, and CFO of InVivo Therapeutics Corp, a research and clinicalstage biomaterials and biotechnology company he founded in . Due to a fractured foot which took months to heal, Mr. Reynolds retired from InVivo Therapeutics in August . He is a coinventor on over neurological biomaterials focused patent applications. As the former Director of Global Business Development at Siemens, Mr. Reynolds was responsible for new business in over countries. He obtained an MBA from MITSloan Fellows Program in Global Innovation and Leadership at Massachusetts Institute of Technology in a Master s of Science in Technology Management from The Wharton School in a Master s of Science in Engineering from University of Pennsylvania in a Master s of Science in Management Information Systems from Temple University in a Master s of Science in Health Administration from Saint Joseph s University in a Master s of Science in Counseling Psychology from Chestnut Hill College in and a Bachelor of Science in Marketing from Rider University in .
  • Derek S. Bridges / Director
    • Derek Bridges has served as an independent member of the Board of Directors of PixarBio since February . Since January , Mr. Bridges has served as President and CEO of Next Level Alignment, Inc., providing advisory services to firms requiring management consulting in the areas of healthcare, education, emerging technologies and their private equity and venture capital funding partners. The firm comprises a network of senior executives and experts in the U.S. Health Insurance markets, sales, virtual education, technology entrepreneurship and the alignment of growth strategies. He received an M.B.A. from the University of Kansas in and an M.S.E. in Technology Management from the University of Pennsylvania s Wharton School in . Mr. Bridges has extensive experience with regulatory filing, bidding and reimbursement with the Centers for Medicare and Medicaid CMS and specifically with the Patient Protection and Affordable Care Act PPACA . He previously served as a senior executive for several of the largest health insurance companies in the U.S. Mr. Bridges previously served as a senior executive for Anthem, Aetna and Delta Dental, developing growth strategies to double revenue/profitability in MM to B organizations.
  • David A. Cass / Director
    • David A. Cass has served as an independent member of the Board of Directors of PixarBio since June . Since September , Mr. Cass has been the Chief Information Security Officer for IBM. He has global responsibility for all aspects of security practices, processes, and policies across the IBM Cloud amp SaaS business unit. From June to September , Mr. Cass served as the Senior Vice President and Chief Information Security Officer for Elsevier, leading an organization of experienced legal, risk and security professionals that provided data protection, privacy, security, and risk management guidance on a global basis for Elsevier. Mr. Cass previously served as the Senior Director of Information Security Risk and Governance for Freddie Mac and rebuilt the risk and governance function and as Vice President of Risk Management for JPMorgan Chase where he was responsible for providing assessment of risk management state, contributing to future direction of risk management, continuity amp disaster recovery. Mr. Cass obtained an MSE from the University of Pennsylvania s Wharton School in , and an MBA from MIT in . He has extensive experience in IT security, risk assessment, risk management, business continuity and disaster recovery, developing security policies and procedures. He has played a key role in leading and building corporate risk and governance and information security organizations in the financial sector.
  • Katrin Holzhaus / Director
    • Katrin Holzhaus cofounded PixarBio as Chief Operating Officer and has served as Chief Administration Officer and a Director of PixarBio since September . Having worked in the executive suite with PixarBio cofounder and CEO Frank Reynolds for almost years she has had a front row view to revolutionary neurological R amp D models that have led to breakthrough treatments for spinal cord injury and pain. Initially with Expand the Knowledge, InVivo Therapeutics Holdings Corp NVIV , and now with PixarBio, Ms. Holzhaus brings complimentary leadership skillsets to PixarBio s operations team and a proven record of success. At PixarBio, Ms. Holzhaus oversees the Company s administrative and resource allocation including longrange financial planning and budgeting, business and contractual services, research support, human resources, facilities planning. From July to August , Ms. Holzhaus served as Senior Executive Assistant at InVivo Therapeutics a pharmaceutical company. From June to July , she was Director of Operations at Magnum Group, Inc., a global communications company supporting clients in the life sciences sector. Ms. Holzhaus received her MBA and MS in Management Information Systems from Temple University, Philadelphia, Pennsylvania in and a Master of Arts from Leipzig University, Germany in .
  • Laura Barker Morse / Director
    • Laura Barker Morse has served as an independent member of the Board of Directors of PixarBio since June . She has been Director of reacHIRE, a venturebacked firm providing training and placement for professional women returning to the workforce, since May . Since May , Ms. Morse has served as Managing Director of Entrepreneurship Ventures Inc., a consulting and coaching firm focused on assisting global entrepreneurs to achieve their full potential. Between and she served as the Human Capital Partner for Atlas Venture, focused on portfolio company team building. She also headed human resources for the firm, coordinating with offices in Europe and in the U.S. to design and implement best in class recruitment, compensation, benefits and training programs. During she cotaught Designing and Leading the Entrepreneurial Venture, an elective at MIT/Sloan School of Business. Ms. Morse obtained her BA in English and Psychology from the University of Iowa in . She also led worldwide recruiting amp expatriate services for S.W.I.F.T. sc Brussels, a global financial telecom consortium. She is a frequent speaker in Europe, Solvay Belgium , Harvard Business School, and MIT/Sloan. Ms. Morse has extensive experience in consulting for global new ventures and specializes in human capital strategies including recruitment, development and reward systems.

Current Share Structure

  • Market Cap: $60,157,482 - 03/15/2018
  • Authorized: 200,000,000 - 11/18/2016
  • Issue and Outstanding: 80,209,976 - 11/18/2016
  • Float: 1,680,000 - 11/18/2016

 


Recent Filings from (OTC: PXRB)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 21 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 15 2018
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: February, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 28 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 22 2017

 

 


Daily Technical Chart for (OTC: PXRB)

Daily Technical Chart for (OTC: PXRB)


Stay tuned for daily updates and more on (OTC: PXRB)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: PXRB)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PXRB is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of PXRB and does not buy, sell, or trade any shares of PXRB. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/